Brainomix secures £4.8m Series C extension led by Parkwalk and Hostplus to fund US growth
The extension brings total Series C financing to £18.8m with participation from US investor Modi Ventures.
Brainomix is a medical imaging company that develops artificial intelligence tools to improve diagnosis and treatment decisions for stroke and lung fibrosis. The firm spun out from the University of Oxford and operates in more than twenty countries.
Oxford-based medical imaging specialist Brainomix has secured £4.8m in an extension to its Series C financing round. The investment was co-led by existing backers Parkwalk and Hostplus via the IP Group Hostplus Innovation Fund, with participation from new US participant Modi Ventures. The latest injection brings total funding in the round to £18.8m.
The capital will be directed towards accelerating the company expansion in the United States and bolstering customer support operations. Brainomix deploys its proprietary artificial intelligence platforms, including Brainomix 360 Stroke and e-Lung, across hospital networks to assist clinicians with rapid assessment and workflow integration.
From the founder
"This investment reflects strong confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care. Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care. With this investment extension, we are well-positioned to enhance customer support across the US and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments."
Michalis Papadakis
CEO at Brainomix
Investor perspective
"Brainomix has built an exceptionally strong platform backed by rigorous clinical validation and real-world evidence showing that Brainomix 360 Stroke can significantly increase endovascular thrombectomy treatment rates and reduce delays in patient triage and transfer, particularly in primary stroke centers. With e-Lung, Brainomix is developing a truly novel technology to accelerate the diagnosis of fibrosing lung disease, enabling earlier treatment options that can improve patient outcomes. We are pleased to join as a new investor and look forward to supporting the company as it expands in the U.S. and accelerates adoption of technologies that meaningfully improve patient outcomes."
Sahir Ali
Founder and general partner, Modi Ventures
Use of funds
- 01Expand into international markets
